FDA Approves TRETTEN® for the Treatment of Congenital Factor XIII A-Subunit Deficiency PLAINSBORO, N.J., Dec. 23, 2013 /PRNewswire/ -- Novo Nordisk today announced the US Food and Drug Administration (FDA) has approved TRETTEN® (Coagulation Factor XIII A-Subunit [Recombinant]) for the routine prophylaxis of bleeding in people with congenital factor XIII (FXIII)...
Dec. 23, 2013 - PR Newswire
U.S. FDA approves Novo Nordisk's drug for rare blood clotting disorder (Reuters) - The U.S. Food and Drug Administration said on Monday it has approved Novo Nordisk's drug Tretten to prevent bleeding in patients with a rare blood clotting disorder. Patients with congenital Factor XIIIA-subunit deficiency do not make enough of the Factor XIII protein that is important for normal blood clotting, the FDA said. Factor XIII is composed of subunits A and B and Factor ...
Dec. 23, 2013 - Reuters via Yahoo! News
FDA approves Novo Nordisk's Tretten to treat rare genetic clotting disorder The U.S. Food and Drug Administration approved Tretten, Coagulation Factor XIII A-Subunit, the first recombinant product for use in the routine prevention of bleeding in adults and children who have a ...
Dec. 23, 2013 - theflyonthewall.com via Yahoo! Finance